Core Viewpoint - The approval of the IND for CS2009, a tri-specific antibody therapy, marks a significant advancement for the company in the treatment of advanced solid tumors, indicating strong confidence in its clinical development potential [1] Company Summary - The company announced that its CS2009 therapy, which targets PD-1, VEGF, and CTLA-4, has received approval for a Phase II clinical trial in China [1] - The CEO, Dr. Yang Jianxin, expressed confidence in accelerating the Phase II study based on promising preliminary data from the Phase I trial [1] - The Phase II trial will utilize a multi-cohort parallel expansion design, covering 15 monotherapy and combination therapy cohorts across 9 solid tumor indications, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) [1] - The trial is currently enrolling participants in Australia, and the approval in China is expected to expedite the clinical development process [1]

Core Insights - Company announced the approval of IND for CS2009, a tri-specific antibody therapy for advanced solid tumors by the NMPA in China [1] Company Developments - CS2009's Phase I study preliminary data has provided confidence to accelerate the Phase II study [1] - The Phase II clinical trial will adopt a multi-cohort parallel expansion design, covering 15 monotherapy/combo therapy cohorts across 9 solid tumor indications, including non-small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC) [1] - The Phase II clinical trial is currently enrolling patients actively in Australia, and the approval of the IND in China will further expedite the clinical development process [1]

Summary of Key Points Core Viewpoint - Recent shareholder equity disclosures for Jin Di Shang Zhi (00535) and Cornerstone Pharmaceuticals-B (02616) were made on November 4, 2025, indicating changes in institutional holdings [1]. Group 1: Jin Di Shang Zhi (00535) - Loh Lian Huat increased holdings from 11.226 million shares to 12.248 million shares, maintaining a holding percentage of 0.07% [2]. Group 2: Cornerstone Pharmaceuticals-B (02616) - Yang Jianxin increased holdings from 70.943 million shares to 71.162 million shares, with a current holding percentage of 4.82% [2]. - The previous holding percentage was 4.81% [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告所作出的前瞻性陳述僅與本文作出該陳述當日的事件或資料有關。除法律規定外，於作出前 瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任 何前瞻性陳述及預料之外的事件。請細閱本公告，並理解我們的實際未來業績或表現可能與預期有 重大差異。本公告中有關我們或任何董事及╱或本公司的意向的陳述或提述乃於本公告刊發日期作 出。任何該等意向均可能因未來發展而出現變動。 CStonePharmaceuticals 基石藥業宣佈CS2009（PD-1/VEGF/CTLA-4三特異性抗體）Ⅱ期臨床試驗聯合療法IND在中國 獲批，深入探索三抗治療潛力 本公告乃由基石藥業(「本公司」連同其附屬公司統稱「本集團」或「基石藥業」)自願作出， 以使本公司股東及潛在投資者瞭解本集團的最新業務發展。 …………………………………………………………………………………………… 基石藥業今日宣佈CS200 ...

Core Viewpoint - 基石药业-B (02616) announces the appointment of Xie Fang as an independent non-executive director and chair of the audit committee, as well as a member of the remuneration committee, nomination committee, and investment committee, effective from November 1, 2025 [1] Group 1 - He Ye resigns from the position of independent non-executive director, chair of the audit committee, and member of the remuneration committee, nomination committee, strategic committee, and investment committee, effective at the end of business on October 31, 2025 [1]

Core Points - 基石药业-B (02616) announced the appointment of Xie Fang as an independent non-executive director, chairman of the audit committee, and member of the remuneration committee, nomination committee, and investment committee, effective from November 1, 2025 [1] - He Ye resigned from his position as an independent non-executive director, chairman of the audit committee, and member of the remuneration committee, nomination committee, strategic committee, and investment committee, effective at the end of business on October 31, 2025, to devote more time to personal matters [1]

Core Viewpoint - 基石药业-B (02616.HK) announces the appointment of Xie Fang as an independent non-executive director and chairman of the audit committee, effective from November 1, 2025 [1] Group 1 - Xie Fang will also serve as a member of the remuneration committee, nomination committee, and investment committee [1] - He Yé has resigned from his positions as independent non-executive director, chairman of the audit committee, and member of the remuneration committee, nomination committee, strategic committee, and investment committee, effective at the end of business on October 31, 2025 [1]

CStone Pharmaceuticals 基石藥業 | | 審核委員會 | 薪酬委員會 | 提名委員會 | 戰略委員會 | 投資委員會 | | --- | --- | --- | --- | --- | --- | | 楊建新博士 | | | | C | | | 李偉博士 | | M | C | | | | Kenneth Walton Hitchner III先生 | | | | | M | | 胡正國先生 | | | | M | C | | 胡定旭先生 | M | C | M | | | | Kenneth Howard Jarrett先生 | M | | | M | | | 謝芳女士 | C | M | M | | M | 執行董事 楊建新博士（ 首席執行官 ） 非執行董事 李偉博士（ 主席 ） Kenneth Walton Hitchner III先生 胡正國先生 獨立非執行董事 胡定旭先生 Kenneth Howard Jarrett先生 謝芳女士 董事會下轄五個董事會委員會。下表列示本公司各董事所在該等委員會的成員資 料。 （於開曼群島註冊成立的有限公司） （股份代號：2616） 董事名單及其 ...

(3) 董事會委員會組成變動 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 CStone Pharmaceuticals 基石藥業 （於開曼群島註冊成立的有限公司） （股份代號：2616） (1) 委任獨立非執行董事； (2) 獨立非執行董事辭任；及 委任獨立非執行董事 基石藥業（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈，謝芳女士（「謝女 士」）已獲委任為獨立非執行董事、本公司審核委員會（「審核委員會」）主席以及薪 酬委員會（「薪酬委員會」）、提名委員會（「提名委員會」）及投資委員會（「投資委員 會」）各自的成員，自2025年11月1日起生效。 謝女士的履歷詳情載列如下： 謝芳女士（又稱Heather Xie），61歲，在營運財務及管理諮詢方面擁有逾30年經 驗。謝女士自2021年起一直擔任中通快遞（開曼）有限公司（一間於香港聯合交易 所有限公司（「聯交所」）主板（港交所：2057）及紐約證券交易所（NYSE：ZTO）兩 地上市的公司） ...

香港联交所最新资料显示，10月21日，首席执行官杨建新增持基石药业-B(02616)30万股，每股作价7.16 港元，总金额为214.8万港元。增持后最新持股数目约为7094.27万股，最新持股比例为4.81%。 ...